Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort
- 17 October 2013
- journal article
- clinical trial
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 21 (5) , 377-380
Abstract
Summary: The population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C‐infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on‐treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa‐2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country‐specific legal and regulatory requirements. This subanalysis includes treatment‐naive HCV mono‐infected patients assigned to receive peginterferon alfa‐2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years.Keywords
Funding Information
- Roche
- F. Hoffmann-La Roche Ltd.
This publication has 9 references indexed in Scilit:
- High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trialsHepatology, 2012
- Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infectionJournal of Hepatology, 2011
- The global health burden of hepatitis C virus infectionLiver International, 2011
- Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis CLiver International, 2010
- Peginterferon alfa‐2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub‐sets of older and younger HCV genotype 1 patientsJournal of Viral Hepatitis, 2009
- Hepatitis C Virus Infection in the ElderlyDrugs & Aging, 2008
- Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening ParticipantsJournal of the Formosan Medical Association, 2007
- Elderly Patients Are at Greater Risk of Cytopenia During Antiviral Therapy for Hepatitis CCanadian Journal of Gastroenterology and Hepatology, 2006
- Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern ItalyHepatology, 1997